Stocks Comparison
Immucell vs Alpha Teknova: revenue, profit, margins and growth compared
Immucell brought in $27.6M of revenue in fiscal 2025, Alpha Teknova $40.5M in fiscal 2025. Revenue changed by +4.3% at Immucell and +7.4% at Alpha Teknova on the year before, so Alpha Teknova grew faster. Immucell kept -3.8% of its revenue as net profit, Alpha Teknova -42.6%. Free cash flow was $1.2M at Immucell and -$9.8M at Alpha Teknova.
Side by side, latest fiscal year
| ICCC | TKNO | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $27.6M | $40.5M |
| Revenue growth | +4.3% | +7.4% |
| Net income | -$1M | -$17.3M |
| Net margin | -3.8% | -42.6% |
| Free cash flow | $1.2M | -$9.8M |
| Free cash flow margin | 4.4% | -24.2% |
| Earnings per share (diluted) | -$0.12 | -$0.32 |
| Cash | $3.8M | $5.9M |
| Debt | $9.1M | $13.1M |
| Price to earnings | n/a | n/a |
| Market value | $90.1M | $500.9M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #396 of 523 · Health care | #376 of 523 · Health care |
Over the years
Questions about Immucell and Alpha Teknova
Which is bigger by revenue, Immucell or Alpha Teknova?
Alpha Teknova is bigger by revenue: $40.5M in fiscal 2025, against $27.6M for Immucell in fiscal 2025.
Which keeps more of its revenue as profit, Immucell or Alpha Teknova?
Immucell had a net margin of -3.8% in fiscal 2025; Alpha Teknova had -42.6% in fiscal 2025.
Which grew revenue faster, Immucell or Alpha Teknova?
In their latest fiscal years revenue changed by +4.3% at Immucell and +7.4% at Alpha Teknova.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.